About
Nanofaber is an innovative company operating in the field of nanotechnology and advanced biomaterials for biomedical and pharmaceutical applications. The company develops micro- and nanostructured drug delivery platforms, with a strong focus on controlled and sustained release systems aimed at the treatment of chronic diseases.
Nanofaber’s core technology includes engineered polymeric microsystems, such as hyaluronic acid–based Microsponges, designed to enhance therapeutic efficacy, active ingredient stability, and patient adherence, while reducing dosing frequency and side effects.
Nanofaber covers multiple stages of the innovation chain, from material design and formulation to preclinical development and functional validation, and actively collaborates with universities, research centres, hospitals, and industrial partners. The company is particularly interested in European collaborative projects in the areas of:
-
chronic and cardiovascular diseases
-
regenerative medicine
-
advanced drug delivery and combination products
-
enabling technologies for personalised medicine
Through a multidisciplinary and translational approach, Nanofaber aims to deliver scalable and clinically relevant technological solutions ready for industrial and clinical exploitation.